Johnson & Johnson cuts adjusted EPS guidance. Johnson & Johnson stock gains 1.21 percent.

Published on 10/07/2026 at 14:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 13, 2026 before market open. Johnson & Johnson stock costs EUR 229.18 on October 7, 2026 versus EUR 226.43.

Comic-Illustration eines Wissenschaftlers mit Spritze und Impfstoffampulle — Pop-Art-Comic zeigt lächelnden Wissenschaftler mit Impfstoff und symbolisiert Innovationskraft von Johnson & Johnson, ISIN US4781601046, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 229.18 at Lang & Schwarz on October 7, 2026 at 2:41 p.m. CEST, plus 1.21 percent versus the prior close of EUR 226.43. The company cut its 2026 adjusted earnings-per-share guidance on July 29, 2026, setting a lower range of USD 10.96-11.11 versus USD 11.60-11.75 previously, as Yahoo Finance reported.

Guidance resets the earnings benchmark

The guidance cut reflects USD 0.64 per share of dilution linked to the Firefly Bio acquisition and a Sail Biomedicines partnership, according to Yahoo Finance. Firefly also carries a USD 1.00 billion in-process research and development charge in the third quarter, making adjusted earnings the key near-term measure.

That reset matters because Johnson & Johnson enters its next report with a stronger revenue profile than its earnings outlook. In the second quarter of 2026, revenue reached USD 25.31 billion, up 6.60 percent from the prior-year quarter, while adjusted earnings per share came to USD 2.90 versus a USD 2.84 consensus estimate, MarketBeat reported.

October results put sales in focus

Johnson & Johnson is scheduled to report third-quarter results before the market open on October 13, 2026, according to Yahoo Finance. The next report will test whether Innovative Medicine and MedTech can sustain the 6.60 percent second-quarter revenue growth while the lower adjusted earnings range absorbs acquisition costs.

IG cited a TipRanks snapshot showing 14 Buy ratings and four Holds among 18 analysts, with an average 12-month target of USD 288.56. Against the USD 252.92 reference price in that snapshot, the target stood 14.09 percent above the price, although that comparison uses the primary-market currency rather than the euro reference quote.

Stock rises with earnings ahead

At Lang & Schwarz, Johnson & Johnson stock was trading at EUR 229.18 on October 7, 2026 at 2:41 p.m. CEST, up 1.21 percent versus the prior close of EUR 226.43. The price sits within the primary-market 52-week range of USD 184.66 to USD 281.07 as of October 7, 2026, while the USD 614.0 billion market capitalization gives the earnings guidance reset broad market relevance.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.